Following liver damage and heart risk in people with fatty liver disease
Observes how fatty liver disease affects liver scarring and heart risk over time.
Plain-language title generated from the registry record
Registry title: Liver Damage and Cardiometabolic Disorders in NAFLD
Key facts
- Where
- Rome, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04036357, who can take part
Where in Italy
- Day Service of Internal Medicine and Metabolic Disorders - Policlinico Umberto I - Sapienza University of RomeRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Roma La Sapienza
- Trial code
- NCT04036357
- Record updated
- 16 August 2019
- Original description
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.Read full original descriptionShow less
Progression of LIver Damage and Cardiometabolic Disorders in Non-alcoholic Fatty Liver dIsease: an Observational Cohort STUDY. The Plinio Study
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.
Inclusion: Patients aged 18 years old or more; Patients with at least on of the following metabolic disorders; Obesity; Diabetes; Arterial hypertension; Dyslipidemia.
Exclusion: concomitant therapy with drugs known to promote liver steatosis (e.g. amiodarone); Average daily consumption of alcohol >20 g in women and of >30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT; presence of hepatitis B surface antigen and antibody to hepatitis C virus; positive tests for autoimmune hepatitis; cirrhosis and other chronic liver diseases; diagnosis of oncological diseases; other chronic infectious or autoimmune disease.